title: Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial.
abstract: The growth fraction of tumors from patients with non-Hodgkin's lymphomas (NHL) has been shown to correlate with survival in retrospective studies. The growth fraction can be evaluated using immunohistochemical techniques employing the Ki-67 monoclonal antibody (MoAb) that marks a nuclear protein present in cycling cells. The purpose of this study was to evaluate the clinical utility of the Ki-67 MoAb for predicting survival. Using a prospective trial design in a multi-institutional cooperative trials group, the proliferative index, clinical outcome, and statistical correlations were independently assessed for previously untreated patients with advanced stages of intermediate- and high-grade histologies of NHL treated on Southwest Oncology Group study (SWOG 8516, Intergroup 0067). The proportion of Ki-67-positive cells was determined on snap-frozen thin tissue sections. A proliferative index of 80% or greater, as determined from prior retrospective studies, identified a group of patients (18%) who had a poor outcome. Overall survival was significantly reduced in these patients with a high Ki-67-associated proliferative index compared with those with a low proliferative index (P = .001). One-year survival estimates were 82% (low proliferative index) versus 18% (high proliferative index). A multivariate regression analysis incorporating commonly used clinical prognostic features confirmed the independent effect of proliferation on survival (relative risk estimate 5.9; 95% confidence interval, 2.2, 16.1). The Ki-67 MoAb identifies a group of patients with rapidly fatal NHL for whom currently available chemotherapy is inadequate.
authors.affiliation: University of Arizona, Tucson.
authors.forename: T P
authors.initials: TP
authors.lastname: Miller
authors.forename: T M
authors.initials: TM
authors.lastname: Grogan
authors.forename: S
authors.initials: S
authors.lastname: Dahlberg
authors.forename: C M
authors.initials: CM
authors.lastname: Spier
authors.forename: R M
authors.initials: RM
authors.lastname: Braziel
authors.forename: P M
authors.initials: PM
authors.lastname: Banks
authors.forename: K
authors.initials: K
authors.lastname: Foucar
authors.forename: C R
authors.initials: CR
authors.lastname: Kjeldsberg
authors.forename: N
authors.initials: N
authors.lastname: Levy
authors.forename: B N
authors.initials: BN
authors.lastname: Nathwani
mesh_terms: D000328:Adult; D000368:Aged; D002455:Cell Division; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000276:immunology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D009687:Nuclear Proteins / Q000032:analysis*; D011379:Prognosis; D011446:Prospective Studies; D015996:Survival Rate
chemical_list: D019394:Ki-67 Antigen; D009363:Neoplasm Proteins; D009687:Nuclear Proteins